Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

v3.22.2
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Summary of Significant Accounting Policies  
Schedule of unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share

    

Year Ended December 31, 

    

2021

    

2020

Common Stock Warrants

 

6,757,180

 

2,726,700

Employee Stock Options

 

515,922

 

246,893

Preferred Stock

 

2,089

 

865,500

Total Shares of Common Stock Issuable

 

7,275,191

 

3,839,093

Schedule of Business Acquisitions by Acquisition, Contingent Consideration

Acquisition

    

Milestone Achievement Condition

    

Contingent Consideration Payable

Bayon

  

Successful completion of Phase 1b

$

0.495 million

Successful completion of Phase 2

$

0.990 million

Successful completion of Phase 3

$

4.000 million

FDA approval

$

1.650 million

Panoptes

 

  

Beginning of Phase 3

$

4.750 million

FDA approval

$

4.750 million

Jade:

 

  

FDA approval

$

2.164 million